Stockscreener 앱 받기
4.03
4.28%
-0.18
시간 외 거래:
4.03
전일 마감가:
$4.21
열려 있는:
$4.23
하루 거래량:
701.70K
Relative Volume:
1.20
시가총액:
$123.64M
수익:
$875.70K
순이익/손실:
$-39.57M
주가수익비율:
-3.0023
EPS:
-1.3423
순현금흐름:
$-33.65M
1주 성능:
+10.41%
1개월 성능:
+12.89%
6개월 성능:
+96.59%
1년 성능:
+33.44%
1일 변동 폭
$3.82
$4.23
1주일 범위
$3.6001
$4.39
52주 변동 폭
$1.90
$4.39
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
명칭
Vistagen Therapeutics Inc
전화
650-577-3600
주소
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
VTGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
4.03 | 129.16M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-07 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-07-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-22 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | 개시 | Robert W. Baird | Outperform |
| 2021-02-18 | 개시 | Jefferies | Buy |
| 2021-01-04 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | 개시 | Maxim Group | Buy |
| 2018-02-08 | 재확인 | Chardan Capital Markets | Buy |
| 2017-03-28 | 개시 | Maxim Group | Buy |
모두보기
Vistagen Therapeutics Inc 주식(VTGN)의 최신 뉴스
Published on: 2025-10-10 09:33:10 - newser.com
Using Ichimoku Cloud for Vistagen Therapeutics Inc. technicalsExit Point & Intraday High Probability Setup Alerts - newser.com
What institutional flow reveals about Vistagen Therapeutics Inc.Dividend Hike & Weekly Momentum Picks - newser.com
Applying Elliott Wave Theory to Vistagen Therapeutics Inc.2025 Sector Review & Growth Oriented Trade Recommendations - newser.com
Published on: 2025-10-10 04:25:39 - newser.com
Tools to assess Vistagen Therapeutics Inc.’s risk profileBuy Signal & Weekly Breakout Watchlists - newser.com
VistaGen Therapeutics (NASDAQ:VTGN) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
What MACD and RSI say about Vistagen Therapeutics Inc.July 2025 Fed Impact & Scalable Portfolio Growth Methods - newser.com
Advanced analytics toolkit walkthrough for Vistagen Therapeutics Inc.July 2025 Short Interest & AI Powered Buy/Sell Recommendations - newser.com
High Stakes Ahead: Vistagen's Fasedienol Trials Could Make Or Break The Story - RTTNews
Sector ETF performance correlation with Vistagen Therapeutics Inc.July 2025 Closing Moves & High Yield Stock Recommendations - newser.com
How moving averages guide Vistagen Therapeutics Inc. trading2025 Winners & Losers & High Accuracy Investment Entry Signals - newser.com
Detecting price anomalies in Vistagen Therapeutics Inc. with AIMarket Growth Review & Free Fast Gain Swing Trade Alerts - newser.com
Has Vistagen Therapeutics Inc. found a price floorJuly 2025 Action & Fast Entry and Exit Trade Plans - newser.com
Understanding Vistagen Therapeutics Inc.’s price movement2025 Top Decliners & Verified Stock Trade Ideas - newser.com
Full technical analysis of Vistagen Therapeutics Inc. stockJuly 2025 Setups & Entry and Exit Point Strategies - newser.com
Vistagen Therapeutics Inc. stock daily chart insightsJuly 2025 PreEarnings & Real-Time Volume Surge Alerts - newser.com
What’s the recovery path for long term holders of Vistagen Therapeutics Inc.Share Buyback & Verified Momentum Stock Watchlist - newser.com
How high can Vistagen Therapeutics Inc. stock go2025 Market Sentiment & Free Safe Capital Growth Stock Tips - newser.com
Vistagen Therapeutics Inc Stock Analysis and ForecastHigh Frequency Trading Trends & Access High Yield Alerts - earlytimes.in
Acute Social Anxiety Disorder Market on Track for Major Expansion by 2034, According to DelveInsight | GlaxoSmithKline Plc, Viatris Inc, Johnson & Johnson, Novartis AG, Pfizer Inc, AstraZeneca Plc - Barchart.com
Tools to monitor Vistagen Therapeutics Inc. recovery probabilityWatch List & Target Return Focused Picks - newser.com
Vistagen Therapeutics Inc (VTGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.74%
자본화:
|
볼륨(24시간):